CH
PALI icon

CVI Holdings’s Palisade Bio PALI Stock Holding History

CVI Holdings’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,667
Closed -$208K – 435
2022
Q4 		$208K Buy
+2,667
New +$155K 0.03% 268

Other funds holding PALI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
OCM
Orion Capital Management Coronado, California $323M AUM 25.22% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

CVI Holdings's PALI Position: Q1 2023 in Review

CVI Holdings sold out of Palisade Bio (PALI) in Q1 2023, closing a stake of 2,667 shares — an estimated $208K sold.

CVI Holdings first reported a position in PALI in Q4 2022 and held it in 1 quarter. The position peaked at $208K in Q4 2022. 8 funds tracked by Wall St. Rank hold PALI as of Q1 2023.

  • CVI Holdings reported no remaining Palisade Bio position as of Q1 2023 after selling out during the quarter.
  • CVI Holdings sold 2,667 Palisade Bio shares in Q1 2023, an estimated $208K.
  • CVI Holdings first reported a position in Palisade Bio in Q4 2022 and held it in 1 quarter.
  • CVI Holdings's Palisade Bio position peaked at $208K in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.